Compare AstraZeneca plc (AZN) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Match Group Inc — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while Match Group Inc trades at $36.82 (market cap $8.45B). The key difference: AstraZeneca plc is far larger — about 29.4× Match Group Inc's market cap, and Match Group Inc pays the higher dividend (2.17%). Which is the better fit depends on your goals.
| AZN | MTCH | |
|---|---|---|
Market Cap | $248.14B | $8.45B |
Sector | Health | Media |
52-Week High | $209.48 | $41.24 |
52-Week Low | $147.06 | $28.90 |
Enterprise Value | $275.41B | $11.42B |
Dividend Yield | 2.01% | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Match Group (MTCH) trades at $36.63, down 0.27% with bearish technical signals despite reasonable valuation metrics (P/E 13.05, P/S 2.66). Recent Q2 2026 earnings missed revenue estimates with $853 million (down 1% YoY) though Tinder engagement improved and Hinge grew 22% YoY. Operating cash flow remains strong at $1.08 billion in 2025, but high debt ($3.85 billion) and negative shareholder equity pose balance sheet concerns.
The outlook is mixed: analyst consensus is Buy (53% of 32 analysts) with $42.33 price target (16% upside), but near-term revenue pressure and Tinder's sluggish performance create headwinds. Investment opportunity lies in Hinge's international expansion and Tinder turnaround potential, while risks include execution missteps, competitive threats, and macroeconomic sensitivity affecting dating app usage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
